The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 20 April 2026•Updated 20 April 2026•

1 min read

Trinity Capital Commits $50M in Growth Capital to Cala Health

Key Facts

1Trinity Capital Inc. committed $50 million in growth capital to Cala Health.

about 1 month ago

Version History

Version 1about 1 month ago

What changed: The story was updated to specify that the funding supports product innovation and to clarify that the Cala kIQ System treats Essential Tremor alongside Parkinson's disease.

Trinity Capital Inc. (Nasdaq: TRIN) has committed $50 million in growth capital to Cala Health, a leader in bioelectronic medicine and wearable neuromodulation therapies. The funding is specifically earmarked to accelerate product innovation and the commercial expansion of the Cala kIQ System, an FDA-cleared wearable device. Notably, the system is designed to manage Essential Tremor in addition to tremors associated with Parkinson’s disease. This investment underscores Trinity Capital's strategic focus on deploying capital into high-growth healthcare technology sectors to generate consistent interest income. By supporting Cala Health’s expanded therapeutic scope, Trinity aims to enhance its portfolio value through medical innovation. Market analysts view this deployment as a bullish signal for Trinity’s active investment strategy and its commitment to scaling non-invasive medical technologies.